Marvel Biosciences’ Mark Williams talks MB-204

In this video, Marvel Biosciences Chief Science Officer Mark Wiliams outlines its MB-204 program, a next-generation A2A antagonist for neurological and neurodevelopmental disorders. The executive discusses its Rett syndrome progress as it moves toward an Orphan Drug Designation and head-to-head preclinical work versus trofinetide. Marvel also highlights a collaboration with the FRAXA Research Foundation to explore MB-204 in Fragile X syndrome, focused on safe, everyday symptom improvement.